GB0707208D0 - Novel disease treatments - Google Patents

Novel disease treatments

Info

Publication number
GB0707208D0
GB0707208D0 GBGB0707208.5A GB0707208A GB0707208D0 GB 0707208 D0 GB0707208 D0 GB 0707208D0 GB 0707208 A GB0707208 A GB 0707208A GB 0707208 D0 GB0707208 D0 GB 0707208D0
Authority
GB
United Kingdom
Prior art keywords
disease treatments
novel disease
novel
treatments
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0707208.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Superiore di Sanita ISS
Original Assignee
Istituto Superiore di Sanita ISS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Superiore di Sanita ISS filed Critical Istituto Superiore di Sanita ISS
Priority to GBGB0707208.5A priority Critical patent/GB0707208D0/en
Publication of GB0707208D0 publication Critical patent/GB0707208D0/en
Priority to PCT/EP2008/004992 priority patent/WO2008125366A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0707208.5A 2007-04-13 2007-04-13 Novel disease treatments Ceased GB0707208D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0707208.5A GB0707208D0 (en) 2007-04-13 2007-04-13 Novel disease treatments
PCT/EP2008/004992 WO2008125366A2 (en) 2007-04-13 2008-04-11 Treatment of autoimmune diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0707208.5A GB0707208D0 (en) 2007-04-13 2007-04-13 Novel disease treatments

Publications (1)

Publication Number Publication Date
GB0707208D0 true GB0707208D0 (en) 2007-05-23

Family

ID=38116725

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0707208.5A Ceased GB0707208D0 (en) 2007-04-13 2007-04-13 Novel disease treatments

Country Status (2)

Country Link
GB (1) GB0707208D0 (en)
WO (1) WO2008125366A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013192100A1 (en) * 2012-06-18 2013-12-27 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods and compositions for detecting jc virus
US9617607B2 (en) 2013-01-08 2017-04-11 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
EP2943593B1 (en) 2013-01-08 2019-04-24 Enzo Biochem, Inc. Diagnosis and treatment of herpesvirus saimiri associated diseases
ITRM20130206A1 (en) 2013-04-05 2014-10-06 Univ Roma GENOTYPE VERSIONS OF EPSTEIN BARR VIRUSES AND THEIR USES AS POSSIBLE RISK PREDICTORS, THERAPEUTIC BIOMARKERS AND TARGETS IN MULTIPLE SCLEROSIS
WO2022146869A1 (en) * 2020-12-29 2022-07-07 The Board Of Trustees Of The Leland Stanford Junior University Diagnostics and therapeutics for ebv in ms and other autoimmune diseases
CN114990240B (en) * 2022-06-01 2024-05-10 昆明理工大学 Multiple qPCR detection reagent for detecting gynecological disease exogenous pathogens

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
EP0397798A4 (en) * 1988-02-03 1991-10-30 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
IL89953A (en) * 1989-02-03 1994-04-12 Xoma Corp Pharmaceutical composition comprising anti-t cell immunotoxin for use in treating autoimmune disease
CA2059824A1 (en) * 1991-02-26 1992-08-27 Thomas M. Aune Hybridomas and monoclonal antibodies that inhibit anti-cd3-stimulated t cell proliferation
WO1993004695A1 (en) * 1991-08-28 1993-03-18 The Wistar Institute T cell receptor-based therapy for rheumatoid arthritis
US7888458B1 (en) * 1993-11-30 2011-02-15 John B. Harley Diagnostics and therapy of epstein-barr virus in autoimmune disorders
US7790153B2 (en) * 1994-04-12 2010-09-07 Research Development Foundation Method of treating rheumatoid arthritis using orally administered type one interferons
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US7273613B1 (en) * 1997-01-13 2007-09-25 The Board of Regents, The University of Oklahoma Diagnostics and therapy of Epstein-Barr virus in autoimmune disorders
KR20080039550A (en) * 1999-05-07 2008-05-07 제넨테크, 인크. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
JP2003514871A (en) * 1999-11-24 2003-04-22 オクラホマ メディカル リサーチ ファウンデーション Assays and treatments for latent virus infection
SE0002045D0 (en) * 2000-05-31 2000-05-31 Sahltech Ab New use
EP1385542A4 (en) * 2000-12-11 2005-11-16 Univ Tufts Treatment and prevention of ebv infection and ebv-associated disorders
WO2003025541A2 (en) * 2001-09-18 2003-03-27 Chiron Corporation Methods for treating multiple sclerosis
DE10148417A1 (en) * 2001-09-29 2003-04-17 Andreas Schwarting Use of interferon-ß for the therapy of systemic lupus erythematosus
AU2002346581A1 (en) * 2001-11-26 2003-06-10 Chiron Corporation Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
AU2002360696A1 (en) * 2001-12-21 2003-07-30 Ilex Oncology, Inc. Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
EP1539246A4 (en) * 2002-07-03 2007-05-16 Brigham & Womens Hospital Central airway administration for systemic delivery of therapeutics
AU2003294210A1 (en) * 2002-07-31 2004-05-04 Seattle Genetics, Inc Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
MXPA05010778A (en) * 2003-04-09 2005-12-12 Genentech Inc Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor.
WO2005009466A1 (en) * 2003-07-24 2005-02-03 Universita' Degli Studi Di Perugia Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells
US20060257363A1 (en) * 2004-03-10 2006-11-16 Pepgen Corporation Treatment using an interferon
MY194883A (en) * 2004-06-04 2022-12-21 Genentech Inc Method for treating multiple sclerosis
US20060188495A1 (en) * 2005-01-13 2006-08-24 Genentech, Inc. Treatment method
NZ565173A (en) * 2005-07-25 2012-01-12 Emergent Product Dev Seattle Single dose use of CD20 scFv for rheumatoid arthritis

Also Published As

Publication number Publication date
WO2008125366A2 (en) 2008-10-23
WO2008125366A3 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
EP2211620A4 (en) Therapeutic compounds
GB0624874D0 (en) Treatment
EP2182833A4 (en) Endoscope
GB0716605D0 (en) Skin antiseptics
GB0600692D0 (en) Well treatment
EP2230910A4 (en) Pre-surgical treatment
GB0711342D0 (en) Well treatment
HK1168420A1 (en) Oximeter
AU318442S (en) Footbath
EP2164324A4 (en) Therapeutic compounds
GB0719518D0 (en) Therapy
GB0724340D0 (en) Novel Therapeutic Agents
GB0707208D0 (en) Novel disease treatments
EP2185568A4 (en) Therapeutic compounds
GB0607952D0 (en) Novel treatment
GB0716784D0 (en) Well treatment
GB0822077D0 (en) Novel treatments
GB0604460D0 (en) Treatment
GB0808690D0 (en) Therapeutic use
GB0717450D0 (en) Medicament
GB0702862D0 (en) Therapeutic compounds
GB0716072D0 (en) Therapy
GB0700635D0 (en) Therapy
GB0708188D0 (en) Therapeutic compounds
GB0710732D0 (en) Treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)